Selected article for: "antiviral therapy and SARS infection"

Author: Gibson, Elena G; Pender, Melissa; Angerbauer, Michael; Cook, Craig; Jones, Barbara; Spivak, Adam M; Swaminathan, Sankar; Spivak, Emily S
Title: Prolonged SARS CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
  • Cord-id: mn62chw0
  • Document date: 2021_4_8
  • ID: mn62chw0
    Snippet: We describe a case of prolonged SARS CoV-2 infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution.
    Document: We describe a case of prolonged SARS CoV-2 infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution.

    Search related documents:
    Co phrase search for related documents
    • additional treatment and lung disease: 1, 2
    • low respiratory and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • low respiratory tract and lung disease: 1, 2, 3